TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28550080
Drug: Intensive phosphate
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive phosphate goal of 2.33‐4.66 mg/dl (0.75‐1.50 mmol/L)
Study: 28550080
Drug: Liberalized target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberalized target of 6.20‐7.75 mg/dl (2.00‐2.50 mmol/L)
Study: 25525835
Drug: Prebiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic mixture (9 g of galactooligosaccharides [GOS] + 1 g of maltodextrins; daily for 5 days)
Study: 23831050
Drug: ARP1 (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARP1 (15-30 mg/kg/day)
Study: 21331949
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tryptophan (Trp) and arginine (Arg) in diet
Study: 17942035
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/24 h)
Study: 17942035
Drug: Sulpiride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (50 mg/8 h) plus Melatonin (3 mg/24 h)
Study: 17942035
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose 50 mg/8 h)
Study: 9651260
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin (median 480 mg daily) and health/psychosocial services
Study: 9651260
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (usually methadone maintenance)
Study: 26494444
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 4.5 mg/kg
Study: 18974711
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) for 11 weeks, consisting of 30 inspiratory efforts performed twice a day
Study: 16669849
Drug: Paroxetine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-40 mg day-1)
Study: 11111206
Drug: α1-blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1-blockers
Study: 11111206
Drug: Anti-hypertensive α1-blockers
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive α1-blockers (terazosin and doxazosin)
Study: 1280145
Drug: Conventional dressings
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressings (petroleum jelly gauze, petroleum jelly gauze with antibiotics, silver sulphadiazine cream)
Study: 3871597
Drug: Intermittent self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent self‐administered therapy (single‐dose trimethoprim‐sulfamethoxazole)
Study: 3871597
Drug: Patient-administered therapy
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-administered therapy with single-dose trimethoprim‐sulfamethoxazole
Study: 24576793
Drug: Drospirenone-containing combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-containing combined oral contraceptives (DRSP24d)
Study: 24576793
Drug: Drospirenone-containing combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-containing combined oral contraceptives (DRSP21d)
Study: 24576793
Drug: Non-drospirenone oral
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-drospirenone oral contraceptives (non-DRSP)
Study: 24576793
Drug: Levonorgestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-containing oral contraceptives (LNG)
Study: 20146168
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy (GHRT)
Study: 11144372
Drug: DTaP/HepB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP/HepB vaccine used to reconstitute lyophilized PRP‐T vaccine administered as a single injection
Study: 11144372
Drug: DTaP/HepB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP/HepB vaccine and PRP‐T vaccine administered as two separate injections
Study: 11144372
Drug: DTaP, HepB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP, HepB and PRP‐T vaccines administered as three separate injections
Study: 11144372
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Hib conjugate vaccine given at 11 to 15 months of age
Study: 8330602
Drug: Morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 50 micrograms kg‐1 (n = 32)
Study: 30834513
Drug: ATB‐346 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATB‐346 (250 mg once daily)
Study: 30834513
Drug: naproxen (550
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (550 mg twice daily)
Study: 29523571
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for 4-6 weeks
Study: 22452807
Drug: Intravenous glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose-insulin-potassium (GIK)
Study: 25335328
Drug: Jiangzhi Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangzhi Tongluo Soft Capsule (JTSC) combined with Atorvastatin Calcium Tablet (ACT)
Study: 25335328
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin Calcium Tablet (ACT) alone
Study: 19717477
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate (n = 212)
Study: 16007327
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate 50 mg/50 mg
Study: 16007327
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate 100 mg
Study: 16007327
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate 150 mg
Study: 16007327
Drug: Daily ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ibandronate 2.5 mg
Study: 16007327
Drug: All monthly
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All monthly regimens
Study: 16007327
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg and 150 mg monthly regimens
Study: 12910557
Drug: Other NSAIDs
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other NSAIDs (regardless of dosage)
Study: 8874334
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg/d for 2 years plus 6 months of intravenous chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Study: 8164053
Drug: Tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 30 mg/d for 2 years
Study: 30517889
Drug: Active CPAP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CPAP treatment for 12 weeks
Study: 15580472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CT with transanal electrical stimulation
Study: 15580472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CT with perineal electrical stimulation
Study: 7561442
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no herbal therapy)
Study: 2161633
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy plus vindesine (3 mg/m2 weekly for 6 weeks)
Study: 2161633
Drug: Vindesine alone
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine alone (3 mg/m2 weekly for 6 weeks)
Study: 30991718
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice with high-dose polyphenols (1177.11 mg GAE)
Study: 30991718
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice with low-dose polyphenols (294.28 mg GAE)
Study: 30991718
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice (both doses)
Study: 28532539
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with platinum chemotherapy
Study: 23727257
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 IV Q3 weeks)
Study: 23727257
Drug: Docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + Vandetanib (100 mg PO daily)
Study: 19389877
Drug: Dapoxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 120 mg
Study: 19389877
Drug: Dapoxetine 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 240 mg
Study: 17498486
Drug: High-dose Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Astragalus injection with cyclophosphamide (CTX)
Study: 17635371
Drug: Peginterferon alpha-2a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2a, 180 microg once weekly
Study: 17635371
Drug: Peginterferon alpha-2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b, 1.0 microg/kg once weekly
Study: 28445888
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inflammatory and psychosocial stress
Study: 24521180
Drug: Community pharmacists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacists (inexperienced in medication review) after receiving 2-day training in medication review
Study: 15811899
Drug: medicines organizer
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medicines organizer (MO)
Study: 8579878
Drug: 120‐hour continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120‐hour continuous infusion 5‐Fu and bolus cisplatin
Study: 2116667
Drug: Thromboembolism prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboembolism prophylaxis with heparin
Study: 28873075
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (30 mg/kg in the first hour followed by 9 mg/kg/h until the end of the surgical procedure)
Study: 23523255
Drug: Protocolised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolised treatment (control)
Study: 18157018
Drug: Propofol (5.7±0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (5.7±0.2 mg/kg/h)
Study: 10333200
Drug: Budesonide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (3 x 1 mg oral pH‐modified release)
Study: 28575774
Drug: Manual-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-based psychosocial group intervention (6 weekly 2-hour sessions)
Study: 20843236
Drug: 0.4% moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% moxifloxacin gel
Study: 20843236
Drug: 1.25% moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% moxifloxacin gel
Study: 20843236
Drug: 0.125% moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% moxifloxacin gel
Study: 11303414
Drug: Emedastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 0.05% twice daily for 42 days
Study: 11303414
Drug: Levocabastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05% twice daily for 42 days
Study: 9247526
Drug: Amiodarone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (800 mg/day for 14 days, 400 mg/day for 50 weeks, then 300 mg/day thereafter)
Study: 8273226
Drug: Preincisional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preincisional lidocaine infiltration (1% lidocaine, 40 ml)
Study: 8273226
Drug: Postincisional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postincisional lidocaine infiltration (1% lidocaine, 40 ml)
Study: 3542342
Drug: L-adrenaline infusion
Normalized name: L-Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-adrenaline infusion
Study: 3542342
Drug: Salbutamol infusion
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol infusion
Study: 27842939
Drug: High-dose baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose baclofen (up to 150mg)
Study: 27842939
Drug: Low-dose baclofen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose baclofen (30mg)
Study: 22608583
Drug: Sugammadex (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (both doses)
Study: 14716113
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment (Control)
Study: 8642232
Drug: Enalaprilat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (2 mg)
Study: 27631987
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection by physiotherapist
Study: 27631987
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection by orthopaedic surgeon
Study: 21148046
Drug: Honey (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey (2 × 20 g/d)
Study: 21148046
Drug: Artificial honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial honey (2 × 20 g/d)
Study: 15273582
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole with paper diary
Study: 15273582
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole with PDA
Study: 11520717
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF-DPI) 50 microg, twice daily
Study: 11520717
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF-DPI) 100 microg, twice daily
Study: 11520717
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF-DPI) 400 microg, twice daily
Study: 3042932
Drug: Detailed discussion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed discussion with the patient's physician about decision making and life support therapy in the event of extreme or incapacitating illness.
Study: 30653978
Drug: No Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Metformin therapy
Study: 11855540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole at 08:00 hr followed by placebo
Study: 11855540
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ranitidine at 22:00 hr
Study: 11855540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole at 22:00 hr
Study: 9665596
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg bid for 3 weeks
Study: 7647826
Drug: Plantago ovata
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago ovata preparation (20 g granules with 200 ml water)
Study: 7647826
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g granules with 200 ml water)
Study: 325342
Drug: delta9-tetrahydrocannabinol (THC)
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: delta9-tetrahydrocannabinol (THC) 15 MG/70 KG
Study: 325342
Drug: Ethanol 0-54
Normalized name: ethanol 0.66 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0-54 g/kg
Study: 325342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of THC and Ethanol
Study: 29993259
Drug: Jidabokuippo (JDI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jidabokuippo (JDI) 7.5 g
Study: 12627404
Drug: Various doses
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various doses of a drug
Study: 2006742
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.25% bupivacaine at 0.125 mL.kg‐1.h‐1 (n = 13)
Study: 2006742
Drug: Repeated bolus
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated bolus injections of 0.5% bupivacaine with epinephrine 1:200,000 at 0.4 mL/kg every sixth hour (n = 12)
Study: 26297325
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g kg(‐1))
Study: 26297325
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (0.2 g kg(‐1))
Study: 22002790
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (random administration of the same tone)
Study: 20080034
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) group: loading dose of selenium as selenite 15.18 micromol over 2 h and thereafter 10.12 micromol/d as a continuous intravenous infusion (CIV) for 10 d
Study: 20080034
Drug: Very-high-dose (VHD)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-high-dose (VHD) group: loading dose of 25.30 micromol over 2 h and thereafter 20.24 micromol as a CIV for 10 d
Study: 16126048
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no feed supplements)
Study: 12385860
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) for 28 days
Study: 12385860
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) for 14 days and dydrogesterone (10 mg) for 14 days
Study: 8077707
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine containing 10 micrograms of S
Study: 8077707
Drug: PreS2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PreS2 + S vaccines (2 + 10 micrograms, 4 + 20 micrograms, or 8 + 40 micrograms)
Study: 2809024
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with MC extract
Study: 30327875
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy for H. pylori-positive gastric low-grade MALT lymphoma
Study: 30327875
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with 25.2 Gy
Study: 30327875
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with 36 Gy
Study: 27978771
Drug: Retention strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention strategies in buprenorphine treatment
Study: 15743000
Drug: Probiotics (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (fermented milk product Cultura containing live lactobacilli (La-5) and bifidobacteria (Bb-12), 500 ml daily for 4 weeks)
Study: 9040746
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of recombinant human NGF (1 or 3 micrograms)
Study: 30245328
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg prednisolone
Study: 21384133
Drug: Irbesartan 300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300, 600, and 900 mg o.d. for 2 months each
Study: 17627404
Drug: Milk supplement
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplement (two sachets of milk powder containing 1000 mg calcium and 80 microg vitamin K(1)) for 24 months
Study: 16135347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of continuous femoral and sciatic nerve block (FEM/SCI)
Study: 14535870
Drug: Propranolol (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (oral, n=12)
Study: 14535870
Drug: Lanreotide SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide SR (intramuscular, 30 mg once weekly, n=12)
Study: 11152019
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with delavirdine, zidovudine and lamivudine, didanosine or zalcitabine for 1 year
Study: 11152019
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with delavirdine
Study: 11152019
Drug: Dual NRTI
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual NRTI therapy (delavirdine plus zidovudine or 2 NRTIs)
Study: 11152019
Drug: Delavirdine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine as a component of protease inhibitor‐containing regimens
Study: 11152019
Drug: Delavirdine-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine-containing combination therapy
Study: 11152019
Drug: Delavirdine-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine-containing treatment